|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-1-19
|
|
pubmed:abstractText |
To compare adjuvant dose-intensive epirubicin and cyclophosphamide chemotherapy administered with filgrastim and progenitor cell support (DI-EC) with standard-dose anthracycline-based chemotherapy (SD-CT) for patients with early-stage breast cancer and a high risk of relapse, defined as stage II disease with 10 or more positive axillary nodes; or an estrogen receptor-negative or stage III tumor with five or more positive axillary nodes.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AebiStefanS,
pubmed-author:BasserRussell LRL,
pubmed-author:Castiglione-GertschMonicaM,
pubmed-author:CinieriSaverioS,
pubmed-author:CoatesAlan SAS,
pubmed-author:GelberRichard DRD,
pubmed-author:GoldhirschAronA,
pubmed-author:GreenMichael DMD,
pubmed-author:International Breast Cancer Study Group,
pubmed-author:MartinelliGiovanniG,
pubmed-author:O'NeillAnneA,
pubmed-author:PeccatoriFedroF,
pubmed-author:PriceKaren NKN,
pubmed-author:VialeGuiseppeG
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
370-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16421418-Adult,
pubmed-meshheading:16421418-Aged,
pubmed-meshheading:16421418-Amenorrhea,
pubmed-meshheading:16421418-Anthracyclines,
pubmed-meshheading:16421418-Antibiotics, Antineoplastic,
pubmed-meshheading:16421418-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16421418-Breast Neoplasms,
pubmed-meshheading:16421418-Chemotherapy, Adjuvant,
pubmed-meshheading:16421418-Cyclophosphamide,
pubmed-meshheading:16421418-Disease-Free Survival,
pubmed-meshheading:16421418-Dose-Response Relationship, Drug,
pubmed-meshheading:16421418-Drug Administration Schedule,
pubmed-meshheading:16421418-Epirubicin,
pubmed-meshheading:16421418-Female,
pubmed-meshheading:16421418-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:16421418-Humans,
pubmed-meshheading:16421418-Lymphatic Metastasis,
pubmed-meshheading:16421418-Middle Aged,
pubmed-meshheading:16421418-Neoplasm Staging,
pubmed-meshheading:16421418-Odds Ratio,
pubmed-meshheading:16421418-Recombinant Proteins,
pubmed-meshheading:16421418-Risk Assessment,
pubmed-meshheading:16421418-Risk Factors,
pubmed-meshheading:16421418-Stem Cells,
pubmed-meshheading:16421418-Survival Analysis,
pubmed-meshheading:16421418-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
|
|
pubmed:affiliation |
CSL Ltd, 45 Poplar Rd,Parkville, Vic 3052, Australia. russell.basser@csl.com.au
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Research Support, N.I.H., Extramural
|
